1313496-17-1

Basic information

• Product Name: N-(2-Mercapto-1-oxopropyl)-L-serine
• Synonyms: N-(2-Mercapto-1-oxopropyl)-L-serine;NGCWQOJBMCFVRB-BKLSDQPFSA-N
• CAS NO: 1313496-17-1
• Molecular Formula: C6H11NO4S
• Molecular Weight: 193.22084
• Product Categories: Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Amino Acids & Derivatives, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 1313496-17-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-Mercapto-1-oxopropyl)-L-serine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-Mercapto-1-oxopropyl)-L-serine(1313496-17-1)
• EPA Substance Registry System: N-(2-Mercapto-1-oxopropyl)-L-serine(1313496-17-1)

Safety Data

• Hazardous Substances Data: 1313496-17-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1313496-17-1 differently. You can refer to the following data:
1. Tiopronin serine analog.
2. N-(2-Mercapto-1-oxopropyl)-L-serine is a serine analog of Tiopronin (T444780).

Relevant articles and documents

METHODS OF TREAT1NG CANCER AND OTHER DISEASES

Disclosed are a method of treating cancer in a cell, a method of enhancing the chemotherapeutic treatment of a cancer treatment agent, a method of reducing resistance of a cancer cell to a chemotherapeutic agent, a method of reducing the amount or activity of an ABC-family mRNA and/or protein, a method of reducing the amount or activity of the ABCB1 mRNA and/or protein or the ABCC1 mRNA and/or protein in an animal cell undergoing cancer treatment, a method of reducing the amount or activity of glutathione and/or Bcl2 in the cancer cell, a method of treating other multidrug resistant diseases, and a method of treating a multidrug resistant cell such as a bacterial multidrug resistant Staphylococcus aureus (MRSA), tuberculosis, fungal infection, or MDR malaria, by administering a compound of the Formula (I): a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R1-R4 are as described herein. Also disclosed are pharmaceutical compositions comprising a compound of formula (I), a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier